Jiangsu Aidea Pharmaceutical Group Co., Ltd.

Jiangsu Aidea Pharmaceutical Group Co., Ltd. (stock code 688488.SH), established in 2009 and listed on the Shanghai Stock Exchange STAR Market in 2020, is a high-tech pharmaceutical company focused on developing and marketing a comprehensive anti-HIV/AIDS product portfolio while leveraging its competitive advantages in the research and production of human urine-derived proteins. The company is a pioneer in China's anti-HIV/AIDS drug R&D, with two innovative drugs successfully approved for marketing.